Stefan Rose-John - Selected Publications#

Google scholar H-index 132 (70,036 citations, i10-index 521)

1. Rose-John S, Jenkins BJ, Garbers C, Moll JM Scheller J (2023) Targeting IL-6 trans-signaling: past, present and future prospects. Nat Rev Immunol 17: 1-16

2. Saad MI, Weng T, Lundy J, Alanazi M, Hodges C, Croagh D, Kumar B, Sagi I, Rose-John S, Jenkins BJ (2022) Blockade of the protease ADAM17 ameliorates experimental pancreatitis. Proc Natl Acad Sci USA 119: e2213744119

3. Bolik J, Krause F, Stevanovic M, Gandraß M, Thomsen I, Schacht S, Rieser E, Müller M, Schumacher N, Fritsch J, Wichert R, Galun E, Bergmann J, Röder C, Schafmayer C, Egberts J-H, Becker-Pauly C, Saftig P, Lucius R, Schneider-Brachert W, Barikbin R, Adam A, Voss M, Hitzl W, Krüger A, Strilic B, Sagi I, Walczak H, Rose-John S and Schmidt-Arras D (2022) Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis. J Exp Med 219: e20201039

4. Del Poggetto E, Ho I, Balestrieri C, Yen E, Zhang S, Citron F, Shah R, Corti D, Diaferia G, Li CY, Loponte S, Carbone F, Hayakawa Y, Valenti G, Jiang S, Sapio L, Jiang H, Dey P, Gao S, Deem AK, Rose-John S, Yao W, Ying H, Rhim AD, Genovese G, Heffernan TP, Maitra A, Wang TC, Wang L, Draetta GF, Carugo A, Natoli G, Viale A (2021) Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science 373 (6561): eabj0486

5. Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Höper H, Mishra N, Blase J, Nikolaus S, Bethge J, Kühbacher T, Röcken C, Chen M, Cottingham I, Petri N, Rasmussen BB, Lokau J, Garbers C, Rose-John S, Waetzig GH and Rosenstiel P (2021) Therapeutic gp130 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology 160: 2354-2366

6. Schumacher N, Gandraß M, Müller M, Lücke K, Krisp C, Häsler R, Khouja M, Bolik J, Hölscher C, Wunderlich T, Rosenstiel P, Schlüter H, Renné T, Mittrücker H-W, Rose-John S and Schmidt-Arras D (2021) Innate immune response is triggered by hepatocytic GP130 signalling. J Hepatol 74: 407-418

7. Werner-Klein M, Grujovic A, Obradovic M, Hoffmann M, Lu X, Kirsch S, Treitschke S, Köstler C, Weidele K, Lahrmann U, Blochberger I, Irlbeck C, Werno C, Polzer B, Guzvic M, Grunewald S, Haunschild G, Patwary N, Schneider E, Buchholz S, Rümmele P, Heine H, Rose-John S & Klein CA (2020) Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency. Nat Commun, 11: 4977

8. Willis EF, MacDonald KPA, Garrido AL, Gillespie ER, Nguyen QH, Bartlett PF, Schroder W, Wadell N, Dale A, Anthony DC, Rose-John S, Ruitenberg MJ, Vukovic J (2020) Repopulating microglia promote brain repair in an IL-6-dependent manner. Cell 180: 833-846

9. Findeisen M, Allen TL, Henstridge DC, Kammoun HL, Brandon AE, Baggio LL, Watt KI, Pal M, Cron L, Estevez E, Yang C, Kowalski GM, O’Reilly L, Egan C, Sun E, Thai LM, Krippner G, Adams TE, Lee RS, Grötzinger J, Garbers C, Risis S, Kraakman MJ, Mellet N, Sligar J, Kimber ET, Young RL, Cowley MA, Bruce CR, Meikle PJ, Baldock PA, Gregorevic P, Biden TJ, Cooney GJ, Keating DJ, Drucker DJ, Rose-John S & Febbraio MA (2019) Treatment of type 2 diabetes and muscle atrophy with the designer cytokine IC7Fc. Nature 574: 63-68

10. Schmidt S, Schumacher N, Schwarz J, Tangermann S, Kenner L, Schlederer M, Sibilia M, Linder M, Altendorf-Hofmann A, Knoesel T, Gruber E, Oberhuber G, Bolik J, Rehman A, Sinha A, Lokau J, Arnold P, Cabron A-S, Zunke F, Becker-Pauly C, Preaudet A, Nguyen P, Huynh J, Afshar-Sterle S, Chand A, Westermann J, Dempsey P, Garbers C, Schmidt-Arras D, Rosenstiel P, Putoczki T, Ernst M, Rose-John S (2018) ADAM17 is required for EGF-R induced intestinal tumors via IL-6 trans-signaling. J Exp Med 215: 1205-1225

11. Garbers G, Heink S, Korn T, and Rose-John S (2018) Interleukin-6: Designing specific therapeutics for a complex cytokine. Nat Rev Drug Disc 17: 395-412

12. Rose-Rose-John S, Winthrop K, Calabrese L (2017) The role of IL-6 in host defense against infections: Immunobiology and Clinical Implications. Nat Rev Rheumatol 13: 399-409

13. Bergmann J, Baumann N, Reichert M, Müller M, Heneweer C, Bolik J, Lücke K, Gruber S, Boretius S, Leuschner I, Becker B, Rabe B, Wunderlich FT, Mittrücker HW, Rose-John S, Schmidt-Arras D (2017) Tumor initiation and growth of hepatocellular carcinoma is driven by IL-6 trans-signaling. Hepatology 65: 89-103

14. Kraakman MJ, Kammoun HL, Allen TL, Deswaerte V, Henstridge DC, Estevez E, Matthews VB, Neill B, White DA, Murphy AJ, Peijs L, Yang C, Risis S, Bruce CR, Du X-J, Bobik A, Lee-Young RS, Kingwell BA, Vasanthakumar A, Shi W, Kallies A, Lancaster GI, Rose-John S, Febbraio MA (2015) Blocking IL-6 trans-signaling prevents high fat diet-induced adipose tissue macrophage recruitment but does not exacerbate weight gain, liver steatosis or insulin resistance. Cell Metabol 21: 403-416

15. Zhang H, Neuhöfer P, Song L, Rabe B, Lesina M, Kurkowski MU, Treiber M, Wartmann T, Regnér S, Thorlacius H, Saur D, Weirich G, Yoshimura A, Halangk W, Mizgerd JP, Schmid RM, Rose-John S, and Algül H (2013) IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J Clin Invest 123: 1019-1031

16. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, Schirmacher P, Hartmann D, Cichy J, Gavrilova O, Schreiber S, Jostock T, Matthews V, Häsler R, Becker C, Neurath MF, Reiß K, Saftig P, Scheller J, Rose-John S (2010) Critical Role of the Disintegrin Metalloprotease ADAM17 for Intestinal Inflammation and Regeneration in Mice. J Exp Med 207: 1617-1624

17. Chow D, He X, Snow AL, Rose-John S, and Garcia KC (2001) Structure of an extracellular gp130 cytokine receptor signaling complex. Science 291: 2150-2155

18. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, and Neurath MF (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nature Med 6: 583-588

19. Jostock T, Müllberg J, Özbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath M and Rose-John S (2001) Soluble gp130 is the natural inhibitor of soluble il-6R transsignaling responses. Eur J Biochem 268:160-167

20. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A Grötzinger J, and Rose-John S (1997) I. A Bioactive Designer Cytokine For Human Hematopoietic Progenitor Cell Expansion. Nature Biotech. 15: 142-145